News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
13,687 Results
Type
Article (780)
Company Profile (18)
Press Release (12888)
Multimedia
Podcasts (2)
Webinars (2)
Section
Business (4490)
Career Advice (17)
Deals (655)
Drug Delivery (2)
Drug Development (2334)
Employer Resources (2)
FDA (221)
Job Trends (277)
News (7242)
Policy (384)
Tag
Academia (37)
Accelerated approval (2)
Adcomms (5)
Allergies (6)
Alliances (1213)
ALS (1)
Alzheimer's disease (13)
Antibody-drug conjugate (ADC) (20)
Approvals (215)
Artificial intelligence (7)
Autoimmune disease (6)
Bankruptcy (4)
Best Places to Work (219)
BIOSECURE Act (5)
Biosimilars (1)
Biotechnology (14)
Bladder cancer (1)
Brain cancer (1)
Breast cancer (2)
Cancer (123)
Cardiovascular disease (12)
Career advice (10)
CAR-T (16)
CDC (1)
Cell therapy (56)
Clinical research (1877)
Collaboration (63)
Compensation (34)
Complete response letters (4)
COVID-19 (103)
CRISPR (7)
C-suite (41)
Cystic fibrosis (1)
Data (169)
Diabetes (13)
Diagnostics (32)
Drug discovery (9)
Drug pricing (1)
Earnings (1494)
Editorial (2)
Employer resources (2)
Events (2530)
Executive appointments (50)
FDA (293)
Fibrodysplasia Ossificans Progressiva (1)
Frontotemporal dementia (1)
Funding (49)
Gene editing (12)
Gene therapy (38)
GLP-1 (19)
Government (53)
Guidances (7)
Healthcare (385)
Immunology and inflammation (13)
Immuno-oncology (1)
Infectious disease (105)
Inflammatory bowel disease (10)
Intellectual property (6)
Interviews (3)
IPO (363)
Job creations (62)
Job search strategy (10)
JPM (2)
Kidney cancer (1)
Labor market (5)
Layoffs (20)
Legal (65)
Liver cancer (2)
Lung cancer (16)
Lymphoma (21)
Machine learning (1)
Management (1)
Manufacturing (29)
MASH (2)
Medical device (66)
Medtech (66)
Mergers & acquisitions (322)
Metabolic disorders (21)
Neurodegenerative disease (8)
Neuroscience (27)
NextGen: Class of 2026 (139)
Non-profit (19)
Now hiring (1)
Obesity (6)
Opinion (2)
Ovarian cancer (4)
Pain (9)
Pancreatic cancer (2)
Parkinson's disease (5)
Patents (11)
Patient recruitment (9)
People (1752)
Pharmacy benefit managers (1)
Phase 1 (855)
Phase 2 (918)
Phase 3 (541)
Pipeline (145)
Policy (14)
Postmarket research (25)
Preclinical (285)
Press Release (1)
Prostate cancer (3)
Psychedelics (1)
Radiopharmaceuticals (2)
Rare diseases (38)
Real estate (115)
Recruiting (1)
Regulatory (384)
Reports (3)
Research institute (63)
Resumes & cover letters (3)
RSV (1)
Schizophrenia (3)
Series A (13)
Series B (4)
Service/supplier (1)
Sickle cell disease (2)
Special edition (2)
Spinal muscular atrophy (1)
Sponsored (2)
Startups (107)
Supply chain (2)
Tariffs (2)
The Weekly (2)
Vaccines (16)
Venture capital (4)
Weight loss (3)
Date
Last 7 days (20)
Last 30 days (53)
Last 365 days (815)
2026 (76)
2025 (836)
2024 (1024)
2023 (1262)
2022 (1595)
2021 (1626)
2020 (1242)
2019 (732)
2018 (540)
2017 (662)
2016 (547)
2015 (591)
2014 (397)
2013 (339)
2012 (292)
2011 (296)
2010 (310)
Location
Africa (16)
Asia (1118)
Australia (91)
California (502)
Canada (123)
China (35)
Colorado (3)
Connecticut (9)
Delaware (14)
Europe (1313)
Florida (33)
Idaho (1)
Illinois (7)
India (9)
Indiana (2)
Japan (16)
Maryland (64)
Massachusetts (227)
Michigan (4)
Minnesota (5)
Nevada (1)
New Jersey (73)
New Mexico (1)
New York (40)
North Carolina (18)
Northern California (221)
Oklahoma (1)
Pennsylvania (68)
South America (9)
Southern California (191)
Texas (38)
United States (1102)
Utah (2)
Virginia (1)
Washington D.C. (2)
Washington State (17)
Wisconsin (2)
13,687 Results for "epimab biotherapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
EpimAb Biotherapeutics Announces Four Upcoming Presentations at the 2025 American Association for Cancer Research Annual Meeting
April 1, 2025
·
2 min read
Press Releases
Medigene and EpimAb Biotherapeutics Enter into a Co-Development Partnership for TCR-Guided T Cell Engagers
February 27, 2025
·
5 min read
Press Releases
Juri Biosciences, a TCG Labs Soleil Portfolio Company, and EpimAb Biotherapeutics Enter into a Worldwide Licensing Agreement for KLK2-Directed T-Cell Engager in Metastatic Prostate Cancer
May 27, 2025
·
3 min read
EpimAb Biotherapeutics and Almirall Announce Bispecific Antibody License Agreement
EpimAb Biotherapeutics and Almirall announced a license agreement on the development of bispecific antibodies for up to three undisclosed target pairs.
October 12, 2023
·
3 min read
Press Releases
Candid Therapeutics and EpimAb Biotherapeutics Enter Into Research Collaboration to Discover and Develop Novel T-Cell Engagers for Autoimmune Indications
December 16, 2024
·
2 min read
EpimAb Biotherapeutics to Present Late-breaking Abstract on Preclinical Results of EMB-07 at the 2024 American Association for Cancer Research Annual Meeting
EpimAb Biotherapeutics is pleased to announce the acceptance of a late-breaking abstract featuring our novel T-cell engager (TCE) EMB-07 as a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, California between April 5-10, 2024.
March 5, 2024
·
2 min read
EpimAb Biotherapeutics to Present a Late-Breaking Abstract of First-in-Human Data of EMB-06 at 2023 SITC Annual Meeting
EpimAb Biotherapeutics is excited to announce that the company will present the first-in-human results for EMB-06 in a late-breaking poster presentation at the 2023 Society for Immunotherapy of Cancer Annual Meeting to be held in San Diego, California, from November 3-5.
October 31, 2023
·
2 min read
EpimAb Biotherapeutics to Present Initial First-in-human Data of EMB-02 at the 2023 ESMO Conference
EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies, is pleased to announce that the company will present the first-in-human results for EMB-02 as a poster display at the 2023 European Society for Medical Oncology (ESMO) Congress on October 23 (local time).
September 19, 2023
·
2 min read
Business
EpimAb Biotherapeutics Appoints Yonghong Zhu, M.D., Ph.D., as Chief Medical Officer
EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies, announced the appointment of Yonghong Zhu, M.D., Ph.D., as Chief Medical Officer.
June 7, 2023
·
2 min read
Press Releases
EpimAb Biotherapeutics and Vignette Bio Announce Strategic Collaboration to Develop EMB-06, a BCMA×CD3 Bispecific Antibody
September 4, 2024
·
3 min read
1 of 1,369
Next
